The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
 
Linda R. Duska
Consulting or Advisory Role - Advance Medical; British Journal of Obstetrics and Gynecology; ClearView Healthcare Partners; Parexel; UpToDate
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Millennium (Inst); Novartis (Inst); Syndax (Inst); Tesaro (Inst)
Other Relationship - Genentech
 
Jubilee Brown
No Relationships to Disclose
 
Danijela Jelovac
No Relationships to Disclose
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); TESARO (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - Novocure; Takeda Milenium
 
William P. McGuire
No Relationships to Disclose
 
Christopher Darus
No Relationships to Disclose
 
Lisa Marie Barroilhet
No Relationships to Disclose
 
Angeles Alvarez Secord
Honoraria - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Tesaro
Consulting or Advisory Role - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Tesaro
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Morphotek (Inst); Prima BioMed (Inst); Tesaro (Inst)